Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L) treatment in participants with locally advanced (Stage IIIb/IIIC) or metastatic (Stage IV) non-squamous NSCLC with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with CIT when administered as 1L treatment in participants with locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) non-squamous NSCLC with serine/threonine kinase 11 (STK11) mutation and no actionable mutations.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main Inclusion Criteria:
Main Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
64 participants in 4 patient groups
Loading...
Central trial contact
BerGenBio Clinical Team
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal